A major international study has found that drugs that help blood clot freeze reduce the risk of life, major and severe blood clots in patients who have not undergone surgery – without increasing vascular problems.
The tested drug, tranexamic acid (TXA), is given to patients at risk for bleeding or vascular complications. The study found that TXA did not increase the deep vein thrombosis known as VTE, heart attackanemia, or other major vascular problems within 30 days after surgery.
In the study, half of the 9,535 patients in 22 countries were given TXA randomized, half placebo. Patients were 45 years of age or older (average age 69); 44% of them are women.
The study is published today in New England Journal of Medicineand at the same time was presented at the ACC 2022 American Psychological Center by senior author PJ Devereaux.
“It is a common problem in patients undergoing surgery without a heart attack and it often results in patients who need to extra blood. Our research shows that tranexamic acid can prevent this problem, ”said Devereaux, a senior fellow at McMaster University and Hamilton Health Sciences (HHS).
“Furthermore, our findings of safe, effective reduction in surgical bleeding have the potential to assist the health system on a broader outcome.”
Devereaux, who is also a professor of medicine and medical research, adds, “The surgical blood transfusion accounts for 40% of all blood transfusions, and more blood products are needed than is available worldwide. today, ”said Devereaux, who is also a professor of medicine and clinical research, evidence and effectiveness at McMaster, and a cardiologist and patient care physician at HHS.
“Reduced bleeding that is healthy for patients can address the challenge of anemia and save lives.”
“In our experiment, tranexamic acid showed a moderate reduction in the risk of bleeding by several measures, and reduced the risk of getting an additional 1 or 2 to 4,” said PHRI scientist and study author Maura Marcucci.
“Considering that 300 million surgeries are performed every year worldwide. tranexamic acid has the potential to have major public and clinical health benefits, “said Marcucci.
PJ Devereaux et al, Troponin I after 30 days of cardiac surgery, New England Journal of Medicine (2022). DOI: 10.1056 / NEJMoa2000803
hintHigh blood pressure decreases in patients not undergoing heart surgery (2022, April 4) Retrieved April 4, 2022 from https://medicalxpress.com/news/2022-04-major-patients- non-cardiac-surgery.html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.
Major bleeding reduced in patients having non-cardiac surgery Source link Major bleeding reduced in patients having non-cardiac surgery